A 37-year-old woman with normal BMI developed subocclusive ileus (near-complete intestinal blockage) after unsupervised use of semaglutide for cosmetic weight loss, highlighting the dangers of off-label GLP-1 drug use.
Intestinal obstruction in a normal-BMI patientA 37-year-old woman without obesity developed functional intestinal blockage from unsupervised semaglutide use, highlighting that GLP-1 drug complications can occur in non-indicated populations
What the researchers found
A 37-year-old woman with normal BMI developed subocclusive ileus (functional intestinal obstruction) following unsupervised, off-label use of semaglutide for cosmetic weight loss purposes.
Why it matters
As semaglutide becomes widely available through non-medical channels (online pharmacies, social media promotion), people without obesity or diabetes are increasingly using it for cosmetic weight loss without medical supervision. This case demonstrates that GLP-1 drugs carry real risks — including potentially life-threatening intestinal complications — even in young, otherwise healthy individuals. It underscores the importance of medical oversight when using these potent medications.
How the study worked
Single case report documenting the clinical presentation, diagnosis, and outcome of a patient who developed gastrointestinal complications from non-prescribed semaglutide use.
What this study cannot tell us
Single case report — the lowest level of clinical evidence. Cannot establish the incidence of this complication or definitively prove the semaglutide caused the ileus. The specific dose, duration of use, and outcome details are minimal in the abstract. No information about whether the patient had other risk factors for ileus.
How to read the evidence
This is a single case report — the lowest tier of clinical evidence. It generates an important safety hypothesis but cannot establish risk levels or causation definitively.
When this study was published
Published in 2025, this case report reflects the current wave of off-label GLP-1 drug use for cosmetic purposes and the emerging safety signals associated with this trend.
The bigger picture
The democratization of GLP-1 drug access through telehealth platforms and compounding pharmacies has created a growing population of unsupervised users taking these drugs for cosmetic reasons. While GLP-1 drugs are remarkably effective for obesity and diabetes, their potent effects on gut motility can cause serious complications — from severe nausea to gastroparesis to, as in this case, intestinal obstruction. This case joins a growing body of safety reports that argue for maintaining prescription oversight and medical monitoring for GLP-1 drugs.
Questions still open
- What is the incidence of ileus and other severe GI complications in people using GLP-1 drugs without obesity?
- Are normal-BMI individuals at higher risk for severe GI side effects from GLP-1 drugs due to less gut adipose tissue?
- Should regulations be tightened around non-prescribed access to GLP-1 receptor agonists?
Common questions
What is subocclusive ileus?
Is it dangerous to use Ozempic for cosmetic weight loss?
Read the original research
Subocclusive ileus following off-label high-dose semaglutide use.
Endocrinology, diabetes & metabolism case reports, 2025(4)
Citation
Nikolaeva, Arina; Vandeputte, Martin. (2025). Subocclusive ileus following off-label high-dose semaglutide use.. Endocrinology, diabetes & metabolism case reports, 2025(4). https://doi.org/10.1530/EDM-25-0081